-
Development of MKK4 inhibitors for liver regeneration Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-15 Jordan Hindson
The kinase MKK4 is a regulator of hepatocyte regeneration. A new study published in Cell reports the development of small-molecule inhibitors of MKK4. HRX215 increased liver regeneration post-hepatectomy in mouse and pig models and increased hepatocyte proliferation in fibrotic mouse livers post-partial hepatectomy. In addition, HRX215 treatment prevented post-hepatectomy liver failure in a lethal
-
Telemedicine for hepatitis C virus treatment in opioid treatment programmes Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-15 Jordan Hindson
A prospective randomized clinical trial (NCT02933970) has compared the efficacy of hepatitis C virus infection treatment via facilitated telemedicine integrated into opioid treatment programmes (n = 290) versus standard-of-care off-site hepatitis specialist referral (n = 312). The study was conducted across opioid treatment programmes in New York, USA. In the telemedicine group, 92.4% of patients initiated
-
Rhythmicity of infant microbiota and dietary effects Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-14 Jordan Hindson
A new study published in Cell Host & Microbe has compared the development of the microbiota in breast-fed and formula-fed infants. In the trial, 210 infants were randomly assigned to be breast-fed or to receive one of four formulas containing varying supplements, such as bifidobacteria or galacto-oligosaccharides, during the first year of life. The researchers found similar faecal bacterial communities
-
Multi-omic links between gut microbiome and cardiovascular disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-14 Jordan Hindson
The Framingham Heart Study is an ongoing observational cohort study to identify risk factors for cardiovascular disease. Xavier and colleagues used data from study participants to investigate links between the gut microbiome and cardiovascular disease. They generated stool metagenomic and metabolomic data from 1,429 study participants. In particular, they identified that Oscillibacter species were
-
Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma Gut (IF 24.5) Pub Date : 2024-05-13 Jun Wen, Xiang Zhang, Chi Chun Wong, Yating Zhang, Yasi Pan, Yunfei Zhou, Alvin Ho-Kwan Cheung, Yali Liu, Fenfen Ji, Xing Kang, Dabin Liu, Jun Yu
Objective Squalene epoxidase (SQLE) promotes metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma (MASH-HCC), but its role in modulating the tumour immune microenvironment in MASH-HCC remains unclear. Design We established hepatocyte-specific Sqle transgenic (tg) and knockout mice, which were subjected to a choline-deficient high-fat diet plus diethylnitrosamine to induce
-
Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and faecal proteome profiles in mice Gut (IF 24.5) Pub Date : 2024-05-13 Paola Paone, Dimitris Latousakis, Romano Terrasi, Didier Vertommen, Ching Jian, Valentina Borlandelli, Francesco Suriano, Malin E V Johansson, Anthony Puel, Caroline Bouzin, Nathalie M Delzenne, Anne Salonen, Nathalie Juge, Bogdan I Florea, Giulio G Muccioli, Herman Overkleeft, Matthias Van Hul, Patrice D Cani
Objective To decipher the mechanisms by which the major human milk oligosaccharide (HMO), 2’-fucosyllactose (2’FL), can affect body weight and fat mass gain on high-fat diet (HFD) feeding in mice. We wanted to elucidate whether 2’FL metabolic effects are linked with changes in intestinal mucus production and secretion, mucin glycosylation and degradation, as well as with the modulation of the gut microbiota
-
Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long‐term nationwide study from the epi‐IIRN Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-14 Luba Plotkin, Rachel Buchuk, Rona Lujan, Gili Focht, Shira Greenfeld, Revital Kariv, Yiska Loewenberg Weisband, Natan Lederman, Eran Matz, Iris Dotan, Ram Reifen, Dan Turner
-
Mitochondrial function and gastrointestinal diseases Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-13 Parsa S. Haque, Neeraj Kapur, Terrence A. Barrett, Arianne L. Theiss
-
Spatial transcriptomic analysis reveals local effects of intratumoral fusobacterial infection on DNA damage and immune signaling in rectal cancer Gut Microbes (IF 12.2) Pub Date : 2024-05-06 William P. Duggan, Batuhan Kisakol, Ina Woods, Mohammedreza Azimi, Heiko Dussmann, Joanna Fay, Tony O’Grady, Barry Maguire, Ian S. Reynolds, Manuela Salvucci, Daniel J. Slade, Deborah A. McNamara, John P. Burke, Jochen H.M. Prehn
Mucinous colorectal cancer (CRC) is a common histological subtype of colorectal adenocarcinoma, associated with a poor response to chemoradiotherapy. The commensal facultative anaerobes fusobacteri...
-
Novel IL-4/HB-EGF-dependent crosstalk between eosinophils and macrophages controls liver regeneration after ischaemia and reperfusion injury Gut (IF 24.5) Pub Date : 2024-05-09 Yang Yang, Long Xu, Constance Atkins, Lily Kuhlman, Jie Zhao, Jong-Min Jeong, Yankai Wen, Nicolas Moreno, Kang Ho Kim, Yu A An, Fenfen Wang, Steve Bynon, Vincenzo Villani, Bin Gao, Frank Brombacher, Raymond Harris, Holger K Eltzschig, Elizabeth Jacobsen, Cynthia Ju
Objective Previous studies indicate that eosinophils are recruited into the allograft following orthotopic liver transplantation and protect from ischaemia reperfusion (IR) injury. In the current studies, we aim to explore whether their protective function could outlast during liver repair. Design Eosinophil-deficient mice and adoptive transfer of bone marrow-derived eosinophils (bmEos) were employed
-
Landscape of the gut mycobiome dynamics during pregnancy and its relationship with host metabolism and pregnancy health Gut (IF 24.5) Pub Date : 2024-05-09 Yuanqing Fu, Wanglong Gou, Ping Wu, Yuwei Lai, Xinxiu Liang, Ke Zhang, Menglei Shuai, Jun Tang, Zelei Miao, Jieteng Chen, Jiaying Yuan, Bin Zhao, Yunhaonan Yang, Xiaojuan Liu, Yayi Hu, An Pan, Xiong-Fei Pan, Ju-Sheng Zheng
Objective The remodelling of gut mycobiome (ie, fungi) during pregnancy and its potential influence on host metabolism and pregnancy health remains largely unexplored. Here, we aim to examine the characteristics of gut fungi in pregnant women, and reveal the associations between gut mycobiome, host metabolome and pregnancy health. Design Based on a prospective birth cohort in central China (2017 to
-
Diagnostic dilemma: sudden onset of multiple skin lesions in a patient with intestinal disease Gut (IF 24.5) Pub Date : 2024-05-09 Cong Dai, Yu-hong Huang
The patient was a 36-year-old man, who had a 4-year history of ulcerative colitis (UC), for which he had received mesalazine, oral prednisolone and infliximab, neither of which had any long-lasting therapeutic benefit. This patient was admitted to our hospital with skin lesions, abdominal pain and diarrhoea. Two types of skin lesions were evident. First, one well-demarcated superficial ulcer, covered
-
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house? Gut (IF 24.5) Pub Date : 2024-06-01 Debby Bogaert, Willem van Schaik
The microbial ecosystem of the human gut (‘the gut microbiome’) plays an important role in human health through a variety of mechanisms, including the degradation of complex carbohydrates, the production of vitamins and other beneficial compounds and by providing a barrier to invading pathogens.1 The gut can also be the source of pathobionts, including the Gram-negatives Escherichia coli , Klebsiella
-
Dietary fibre (and animal products) modulate the association between tryptophan intake, gut microbiota and type 2 diabetes: but how? Gut (IF 24.5) Pub Date : 2024-06-01 Lin Shi, Rikard Landberg
There is an increased interest in the interplay among diet, gut microbiota and health. Studies have often investigated the influence of diets, foods and dietary components on gut microbiota or whether microbiota can modify the effect of dietary interventions and the role of such modifications on health outcomes.1 This has been fueled by promising results emerging from large landmark studies pinpointing
-
Antiobesity interventions: options, evidence and value Gut (IF 24.5) Pub Date : 2024-06-01 Elena B Elkin, Chin Hur
Adults with obesity have more choices than ever before of therapies that reduce body mass index (BMI) and consequently improve related chronic health conditions. Bariatric procedures are among the most well-studied options with the longest follow-up. Despite achieving the greatest reductions in BMI and rates of diabetes remission, uptake of bariatric surgery remains low. Endoscopic sleeve gastroplasty
-
Enhancing the opportunities for cholangiocarcinoma precision therapy Gut (IF 24.5) Pub Date : 2024-06-01 Reka Toth, Paul J Brindley, Javier Vaquero
Cholangiocarcinoma (CCA), the second most prevalent liver cancer, encompasses a heterogenous group of bile duct malignancies. It predominantly arises from the epithelial cells lining the bile ducts termed cholangiocytes. Most CCA are highly desmoplastic adenocarcinomas, enmeshed in a tumour immune microenvironment. It exhibits a poor prognosis owing to its invasiveness and therapeutic resistance. Based
-
Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma Gut (IF 24.5) Pub Date : 2024-06-01 Marina Barcena-Varela, Pedro Berraondo
The advent of immune checkpoint inhibitors, particularly monoclonal antibodies (mAbs) that target the programmed cell death protein 1 (PD-1) or its ligand (PD-L1), has revolutionised cancer treatment across various malignancies. Despite this groundbreaking progress, a considerable cohort of patients fails to derive benefit from anti-PD(L)1 mAb therapy due to primary and secondary resistance mechanisms
-
Impact of power consumption and power saving for GI endoscopy (power on study) on reducing CO2 emissions Gut (IF 24.5) Pub Date : 2024-06-01 Anna Fichtl, Veronika Tacheva, Niklas Sturm, Karim Hamesch, Doerte Wichmann, Benjamin Mayer, Martin Müller, Martin Wagner, Thomas Seufferlein, Benjamin M Walter
Endoscopy is among the top three contributors to CO2 emissions in hospitals, with power consumption being a key factor that can be directly addressed. Our multicentre study measured power consumption during endoscopic procedures, offering easily implementable approaches for energy conservation (figure 1). Comparing a 30-day period with special energy-saving measures to a baseline period, we observed
-
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma Gut (IF 24.5) Pub Date : 2024-06-01 Massimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, Gaius Longcroft-Wheaton, Alexander W Phillips, James Gossage, Philip V Kaye, Kieran G Foley, Tom Crosby, Sophie Nelson, Helen Griffiths, Muksitur Rahman, Gill Ritchie, Amy Crisp, Stephen Deed, John N Primrose
Barrett’s oesophagus is the only known precursor to oesophageal adenocarcinoma, a cancer with very poor prognosis. The main risk factors for Barrett’s oesophagus are a history of gastro-oesophageal acid reflux symptoms and obesity. Men, smokers and those with a family history are also at increased risk. Progression from Barrett’s oesophagus to cancer occurs via an intermediate stage, known as dysplasia
-
Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study) Gut (IF 24.5) Pub Date : 2024-06-01 Iain Robert Louis Kean, John A Clark, Zhenguang Zhang, Esther Daubney, Deborah White, Paloma Ferrando-Vivas, Gema Milla, Brian Cuthbertson, John Pappachan, Nigel Klein, Paul Mouncey, Kathy Rowan, John Myburgh, Theodore Gouliouris, Stephen Baker, Julian Parkhill, Nazima Pathan, ARCTIC research team
Objective Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control. Design We conducted shotgun
-
Association of healthy lifestyle behaviours with incident irritable bowel syndrome: a large population-based prospective cohort study Gut (IF 24.5) Pub Date : 2024-06-01 Fai Fai Ho, Hui Sun, Hong Zheng, David C N Wong, Yin-Yan Gao, Chen Mao, Yin Ting Cheung, Chun Sing Lam, Maggie H Wang, Irene Xin-Yin Wu, Justin C Y Wu, Vincent C H Chung
Objectives To evaluate the association between healthy lifestyle behaviours and the incidence of irritable bowel syndrome (IBS). Design Population-based prospective cohort study. Setting The UK Biobank. Participants 64 268 adults aged 37 to 73 years who had no IBS diagnosis at baseline were enrolled between 2006 and 2010 and followed up to 2022. Main exposure The five healthy lifestyle behaviours studied
-
Genetic and transcriptomic landscape of colonic diverticulosis Gut (IF 24.5) Pub Date : 2024-06-01 Jungkyun Seo, Hongwei Liu, Kristin Young, Xinruo Zhang, Temitope O Keku, Corbin D Jones, Kari E North, Robert S Sandler, Anne F Peery
Objective Colonic diverticulosis is a prevalent condition among older adults, marked by the presence of thin-walled pockets in the colon wall that can become inflamed, infected, haemorrhage or rupture. We present a case–control genetic and transcriptomic study aimed at identifying the genetic and cellular determinants underlying this condition and the relationship with other gastrointestinal disorders
-
A mucus production programme promotes classical pancreatic ductal adenocarcinoma Gut (IF 24.5) Pub Date : 2024-06-01 Claudia Tonelli, Georgi N Yordanov, Yuan Hao, Astrid Deschênes, Juliene Hinds, Pascal Belleau, Olaf Klingbeil, Erin Brosnan, Abhishek Doshi, Youngkyu Park, Ralph H Hruban, Christopher R Vakoc, Alexander Dobin, Jonathan Preall, David A Tuveson
Objective The optimal therapeutic response in cancer patients is highly dependent upon the differentiation state of their tumours. Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer that harbours distinct phenotypic subtypes with preferential sensitivities to standard therapies. This study aimed to investigate intratumour heterogeneity and plasticity of cancer cell states in PDA in order to
-
Optimal age to discontinue long-term surveillance of intraductal papillary mucinous neoplasms: comparative cost-effectiveness of surveillance by age Gut (IF 24.5) Pub Date : 2024-06-01 Tsuyoshi Hamada, Hiroki Oyama, Ataru Igarashi, Yoshikuni Kawaguchi, Mihye Lee, Hiroki Matsui, Nobuaki Michihata, Yousuke Nakai, Kiyohide Fushimi, Hideo Yasunaga, Mitsuhiro Fujishiro
Objective Current guidelines recommend long-term image-based surveillance for patients with low-risk intraductal papillary mucinous neoplasms (IPMNs). This simulation study aimed to examine the comparative cost-effectiveness of continued versus discontinued surveillance at different ages and define the optimal age to stop surveillance. Design We constructed a Markov model with a lifetime horizon to
-
Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies Gut (IF 24.5) Pub Date : 2024-06-01 Jing Han Hong, Chern Han Yong, Hong Lee Heng, Jason Yongsheng Chan, Mai Chan Lau, Jianfeng Chen, Jing Yi Lee, Abner Herbert Lim, Zhimei Li, Peiyong Guan, Pek Lim Chu, Arnoud Boot, Sheng Rong Ng, Xiaosai Yao, Felicia Yu Ting Wee, Jeffrey Chun Tatt Lim, Wei Liu, Peili Wang, Rong Xiao, Xian Zeng, Yichen Sun, Joanna Koh, Xiu Yi Kwek, Cedric Chuan Young Ng, Poramate Klanrit, Yaojun Zhang, Jiaming Lai, David
Objectives Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify
-
Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy Gut (IF 24.5) Pub Date : 2024-06-01 Ning Cai, Kun Cheng, Yue Ma, Sha Liu, Ran Tao, Yani Li, Danfeng Li, Bin Guo, Wenlong Jia, Huifang Liang, Jianping Zhao, Limin Xia, Ze-yang Ding, Jinhong Chen, Wanguang Zhang
Objective The gain of function (GOF) CTNNB1 mutations (CTNNB1 GOF ) in hepatocellular carcinoma (HCC) cause significant immune escape and resistance to anti-PD-1. Here, we aimed to investigate the mechanism of CTNNB1 GOF HCC-mediated immune escape and raise a new therapeutic strategy to enhance anti-PD-1 efficacy in HCC. Design RNA sequencing was performed to identify the key downstream genes of CTNNB1
-
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis Gut (IF 24.5) Pub Date : 2024-06-01 Hashem El-Serag, Fasiha Kanwal, Jing Ning, Hannah Powell, Saira Khaderi, Amit G Singal, Sumeet Asrani, Jorge A Marrero, Christopher I Amos, Aaron P Thrift, Michelle Luster, Abeer Alsarraj, Luis Olivares, Darlene Skapura, Jenny Deng, Emad Salem, Omar Najjar, Xian Yu, Hao Duong, Michael E Scheurer, Christie M Ballantyne, Salma Kaochar
Background Inflammatory and metabolic biomarkers have been associated with hepatocellular cancer (HCC) risk in phases I and II biomarker studies. We developed and internally validated a robust metabolic biomarker panel predictive of HCC in a longitudinal phase III study. Methods We used data and banked serum from a prospective cohort of 2266 adult patients with cirrhosis who were followed until the
-
PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans Gut (IF 24.5) Pub Date : 2024-06-01 Andreas Geier, Jonas Trost, Ke Wang, Clemens Schmid, Marcin Krawczyk, Stephan Schiffels
Objective Fat deposition is modulated by environmental factors and genetic predisposition. Genome-wide association studies identified PNPLA3 p.I148M (rs738409) as a common variant that increases risk of developing liver steatosis. When and how this variant evolved in humans has not been studied to date. Design Here we analyse ancient DNA to track the history of this allele throughout human history
-
Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers Gut (IF 24.5) Pub Date : 2024-06-01 Jonel Trebicka, Ruben Hernaez, Debbie Lindsay Shawcross, Alexander L Gerbes
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation
-
Revisiting the donor screening protocol of faecal microbiota transplantation (FMT): a systematic review Gut (IF 24.5) Pub Date : 2024-06-01 Rita WY Ng, Priyanga Dharmaratne, Sunny Wong, Peter Hawkey, Paul Chan, Margaret Ip
We read with interest the recent work by Haifer et al ,1 which highlighted the importance of donor selection in determining the clinical efficacy of treating ulcerative colitis (UC) using faecal microbiota transplantation (FMT), with one donor having 100% efficacy compared with a second donor (36% efficacy). Considering the impact of COVID-19 pandemic on FMT, updated guidance including patient selection
-
Basal levels of microbiota-driven subclinical inflammation are associated with anastomotic leak in patients with colorectal cancer Gut (IF 24.5) Pub Date : 2024-06-01 Roy Hajjar, Gabriela Fragoso, Manon Oliero, Ahmed Amine Alaoui, Annie Calvé, Hervé Vennin Rendos, Thibault Cuisiniere, Nassima Taleb, Sophie Thérien, François Dagbert, Rasmy Loungnarath, Herawaty Sebajang, Frank Schwenter, Ramses Wassef, Richard Ratelle, Eric Debroux, Carole Richard, Manuela M Santos
In our recent publication in Gut ,1 we showed that preoperative gut microbiota was causally linked to the development of anastomotic leak (AL) after colorectal cancer (CRC) surgery. AL results from impaired healing of the colonic wound and leads to the leakage of intestinal content into the abdomen. Using faecal microbiota transplantation (FMT) in mice with faecal samples from 18 patients with CRC
-
Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention Gut (IF 24.5) Pub Date : 2024-06-01 Tanya M Monaghan, Aslihan Ugun-Klusek, Mattea Finelli, Pratik Gurnani, Lisa Chakrabarti, Dina Kao, Cameron Alexander, Christos Polytarchou
We read with interest the recent article by Zhang et al that reported a higher risk of developing dementia in patients with inflammatory bowel disease (IBD), with the largest increase in Alzheimer’s disease (AD).1 These findings align with a growing body of evidence which links gut inflammation or leaky gut with neurodegeneration. Lee et al discussed the known shared pathophysiological links between
-
Multiple and diverse consequences of inhibiting gastric acid secretion: remembering the bicentenary of William Prout’s discovery Gut (IF 24.5) Pub Date : 2024-06-01 D Mark Pritchard, Robert Logan
We have read with interest several recent papers in Gut that have reported novel insights about the potential consequences of reduced gastric acid secretion. These include reports that proton pump inhibitor (PPI) use increases the risks of developing diverse diseases including gastric adenocarcinoma1 2 and severe COVID-19 infection.3 An intriguing recent paper has also shown that pathological suppression
-
Autoimmune gastritis may be less susceptible to cancer development than Helicobacter pylori-related gastritis based on histological analysis Gut (IF 24.5) Pub Date : 2024-06-01 Junya Arai, Ryota Niikura, Yoku Hayakawa, Yoshihiro Hirata, Tetsuo Ushiku, Mitsuhiro Fujishiro
We read with great interest the recent publication by Rugge et al ,1 in which the authors conducted a cohort study to evaluate the association between autoimmune gastritis (AIG) and gastric cancer (GC). No excess risk of gastric or other malignancies was observed over a cumulative follow-up time of 10 541 person-years, except for (marginally significant) thyroid cancer (standardised incidence ratio=3
-
Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain Gut (IF 24.5) Pub Date : 2024-06-01 Ayushi Chauhan, Sarah Lucas, Mayur Garg
We read with interest the paper by Zoller et al comparing the rate of hypophosphataemia with ferric carboxymaltose (FCM) versus ferric derisomaltose (FDI) infusions in patients with inflammatory bowel disease (IBD).1 The higher rate of hypophosphataemia following FCM replicates findings of other studies in patients with and without IBD.2 3 Iron deficiency anaemia is associated with reduced quality
-
Short versus long endoscopic myotomy: how short is too short and how long is too long? Gut (IF 24.5) Pub Date : 2024-06-01 Zaheer Nabi, D Nageshwar Reddy
We read with great interest the study by Familiari et al entitled ‘Long versus short peroral endoscopic myotomy (POEM) for the treatment of achalasia: results of a non-inferiority randomised controlled trial’.1 Short myotomy was non-inferior to long myotomy with regard to clinical success at 2 years with the added advantage of reduced procedure time. Gastro-oesophageal reflux was similar in both the
-
Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease Gut (IF 24.5) Pub Date : 2024-06-01 Mads Israelsen, Camila Alvarez-Silva, Bjørn Stæhr Madsen, Camilla Dalby Hansen, Nikolaj Christian Torp, Stine Johansen, Johanne Kragh Hansen, Katrine Prier Lindvig, Jeanlouis Insonere, Virginie Riviere, Helene Bæk Juel, Asker Brejnrod, Lars Juhl Jensen, Maja Thiele, Benjamin Lelouvier, Torben Hansen, Manimozhiyan Arumugam, Aleksander Krag, MicrobLiver consortium
We read with great interest the review by Tranah et al ,1 which highlighted that alcohol consumption, alterations in the gut microbiome and impairment of the gut barrier function were linked to the development of alcohol-related liver disease (ALD). However, the impact of acute alcohol consumption on the circulating microbiome in patients with ALD remains unclear. To address this gap, we conducted
-
Rare cause of obstructive jaundice Gut (IF 24.5) Pub Date : 2024-06-01 Sota Nakagami, Toshihiro Morita, Shujiro Yazumi
An 85-year-old woman, with a high-grade fever (40°C) and abdominal pain, was referred to our hospital. Blood examination revealed an elevated white blood cell count (25.8×10⁹/L) and elevated levels of C reactive protein (8.54 mg/dL), alanine aminotransferase (95 IU/L), aspartate transaminase (138 IU/L), alkaline phosphatase (804 IU/L), gamma-glutamyl transpeptidase (703 IU/L), and total (5.0 mg/dL)
-
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-10 Rupert W. Leong, Vipul Jairath, Christopher Ma
LINKED CONTENTThis article is linked to Aliu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17988 and https://doi.org/10.1111/apt.18031.
-
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-10 Arta Aliu, Daan H. C. A. Bosch, Daniel Keszthelyi, Ashkan Rezazadeh Ardabili, Jean‐Frederic Colombel, Rachel Sawyer, Hans Törnblom, Ailsa Hart, Daisy M. A. E. Jonkers, Marieke J. Pierik, Zlatan Mujagic
LINKED CONTENTThis article is linked to Aliu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17988 and https://doi.org/10.1111/apt.18027.
-
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui
-
Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Hsin‐Che Lin, Wen‐Juei Jeng, Hwai‐I Yang
LINKED CONTENTThis article is linked to Lin et al papers. To view these articles, visit https://doi.org/10.1111/apt.17915 and https://doi.org/10.1111/apt.17965.
-
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 David Bergman, Jonas F. Ludvigsson
LINKED CONTENTThis article is linked to Bergman et al papers. To view these articles, visit https://doi.org/10.1111/apt.17708 and https://doi.org/10.1111/apt.18010.
-
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Fang Yan, Pengshuang Shi, Shimin Wu, Jie Yang, Dejun Cui
LINKED CONTENTThis article is linked to Bergman et al. papers. To view these articles, visit https://doi.org/10.1111/apt.17708 and https://doi.org/10.1111/apt.18018.
-
Human gut-associated Bifidobacterium species salvage exogenous indole, a uremic toxin precursor, to synthesize indole-3-lactic acid via tryptophan Gut Microbes (IF 12.2) Pub Date : 2024-05-05 Cheng Chung Yong, Takuma Sakurai, Hiroki Kaneko, Ayako Horigome, Eri Mitsuyama, Aruto Nakajima, Toshihiko Katoh, Mikiyasu Sakanaka, Takaaki Abe, Jin-Zhong Xiao, Miyuki Tanaka, Toshitaka Odamaki, Takane Katayama
Indole in the gut is formed from dietary tryptophan by a bacterial tryptophan-indole lyase. Indole not only triggers biofilm formation and antibiotic resistance in gut microbes but also contributes...
-
Commensal microbiota-derived metabolite agmatine triggers inflammation to promote colorectal tumorigenesis Gut Microbes (IF 12.2) Pub Date : 2024-05-05 Yu Lu, Aoxi Cui, Xiaobo Zhang
Colorectal cancer (CRC), a malignant tumor worldwide, is associated with gut microbiota. The influence of gut microbe-derived metabolites on CRC has attracted a lot of attention. However, the role ...
-
Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer Gut (IF 24.5) Pub Date : 2024-05-06 Huisi He, Shuzhen Chen, Yong Yu, Zhecai Fan, Youwen Qian, Yaping Dong, Yuting Song, Caiming Zhong, Xiaojuan Sun, Qiqi Cao, Shiyao Li, Weihan Huang, Wenxin Li, Mingzhu Zhuang, Jinxian Yang, Xianming Wang, Jiaqian Wang, Dongfang Wu, Hongyang Wang, Wen Wen
Objective Elucidating complex ecosystems and molecular features of gallbladder cancer (GBC) and benign gallbladder diseases is pivotal to proactive cancer prevention and optimal therapeutic intervention. Design We performed single-cell transcriptome analysis on 230 737 cells from 15 GBCs, 4 cholecystitis samples, 3 gallbladder polyps, 5 gallbladder adenomas and 16 adjacent normal tissues. Findings
-
Perplexing case of abdominal pain with eosinophilia and fasciitis Gut (IF 24.5) Pub Date : 2024-05-06 Robert Sean O'Neill, Logan Gardner, Anthony Kelleher, Roger Pamphlett, Laila Girgis, Alina Stoita
A 34-year-old man presented to our institution for review with recurrent abdominal pain, constipation, lethargy, fevers and episodic migratory soft tissue severe cellulitis of the limbs after minimal exercise. This was on a background of a diagnosis of eosinophilic enterocolitis at the age of 10 when due to recurrent abdominal pain, endoscopy was performed with biopsies showing eosinophilic infiltration
-
-
Editorial: Hepatitis C virus eradication improves skeletal muscle mass Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Catherine Jia Lin Tian, Jing Hieng Ngu
LINKED CONTENTThis article is linked to Coelho et al papers. To view these articles, visit https://doi.org/10.1111/apt.17950 and https://doi.org/10.1111/apt.18005
-
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Raphael Mohr, Frank Tacke, Christoph Roderburg
LINKED CONTENTThis article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.17985
-
Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Marta Paula Pereira Coelho, Thais Pontello de Vries, Aline Marcos Pires, Milena Pereira Parreira, Érika Ramos de Alvarenga, Rodrigo Dias Cambraia, Rodrigo Ribeiro dos Santos, Juliana Maria Trindade Bezerra, Enrico Antonio Colosimo, Gifone Aguiar Rocha, Luciana Diniz Silva
LINKED CONTENTThis article is linked to Coelho et al papers. To view these articles, visit https://doi.org/10.1111/apt.17950 and https://doi.org/10.1111/apt.17978
-
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Shuyao Song, Jun Lv, Liming Li, Yuanjie Pang
LINKED CONTENTThis article is linked to Song et al papers. To view these articles, visit https://doi.org/10.1111/apt.17963 and https://doi.org/10.1111/apt.17983
-
Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Gong Feng, Calvin Q. Pan, Ming‐Hua Zheng
Editors, We read with great interest the recent article regarding resmetirom—a promising treatment option for metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.1 In fact, another groundbreaking hallmark of resmetirom is that the US Food and Drug Administration (FDA) does not require a liver biopsy to determine a patient's eligibility for the medication.2 Consequently, non-invasive
-
Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Mikkel Malham, Sabine Jansson, Helene Ingels, Marianne Hørby Jørgensen, Naja Hulvej Rod, Vibeke Wewer, Matthew P. Fox
We are grateful to Dr. Henderson for the kind words in his editorial1 and for accurately summarising our paper.2 As Dr. Henderson recognised, cancer was a leading cause of mortality in our nationwide cohort of patients diagnosed with paediatric-onset immune-mediated inflammatory disease (pIMID). This suggests that IMID affects the risk of cancer, which is well known in paediatric-onset inflammatory
-
Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Annalisa Schiepatti, Stiliano Maimaris, Federico Biagi, David S. Sanders
We read with interest the letter by Mohamedrashed et al. highlighting the crucial homeostatic role of the renin–angiotensin system (RAS) for gut homeostasis, and its potential involvement as a key player in the pathogenesis of angiotensin II receptors blockers (ARBs)-associated enteropathy and other gastrointestinal disorders such as inflammatory bowel disease (IBD).1 A bidirectional interaction between
-
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Angelo Armandi, Detlef Schuppan, Jörn M. Schattenberg
On behalf of all co-authors of our recently published paper,1 we thank Dr. Kranidioti and Dr. Deutsch for the analysis and insightful comments provided.2 The basis of the present and future management of metabolic dysfunction-associated steatotic liver disease (MASLD) are lifestyle interventions with or without potential pharmacological treatments.3 The MASLD covers a broad spectrum of liver phenotypes
-
Tu1487 A RARE CASE OF ACUTE PANCREATITIS CAUSING DUODENAL OBSTRUCTION Gastroenterology (IF 29.4) Pub Date : 2024-05-04 Sohrab Zand, Sristee Niraula, Raymond Wadie, Manish Thakur
-
Tu1485 EARLY POSTOPERATIVE OUTCOME COMPARING CHRONIC PANCREATITIS VS. PANCREATIC HEAD CARCINOMA AFTER PYLORUSPRESERVING PANCREATIC HEAD RESECTION ACCORDING TO TRAVERSO-LONGMIRE AT A UNIVERSITY HOSPITAL Gastroenterology (IF 29.4) Pub Date : 2024-05-04 Max Grabowski, Ronny Otto, Aristotelis Perrakis, Roland Croner, Henry Ptok, Frank Meyer
-
Tu1484 LAPAROSCOPIC PANCREATICODUODENECTOMY FOR PANCREATIC CANCER: ARE OUTCOMES WORSE IN EMERGENCY SETTINGS? Gastroenterology (IF 29.4) Pub Date : 2024-05-04 Osayande Osagiede, Yan Bi, Massimo Raimondo, Frank Lukens